Active
Verified
Last Updated: 25 April 2026
Publication: 8 April 2026
PROJECT DESCRIPTION
The Khan Tengri Biopharma project involves the construction of a modern full-cycle biopharmaceutical manufacturing complex in the Alatau Special Economic Zone in Kazakhstan. The facility is designed to produce a wide range of pharmaceutical products using advanced manufacturing technologies. The plant is planned to manufacture 58 types of medicines, including 27 international nonproprietary names (INNs). A major feature of the project is the establishment of a full production cycle, including the local manufacturing of active pharmaceutical ingredients (APIs), which are usually imported. The project aims to support Kazakhstan’s national strat... Read more
Involved Companies & Contacts
INVOLVED COMPANIES & CONTACTS
COMPANY 1 INFO
COMPANY:
░░░░░░░░░░░░░░░░░░░░░░░
ROLE:
░░░░░░░░░░░░░░░░░░░░░░░
ADDRESS:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
PHONE:
░░░░░░░░░░░░░░
EMAIL:
░░░░░░░░░░░░░░░
WEBSITE:
░░░░░░░░░░░░░░░░░░░░░░░
OTHER LINKS:
7. party1CompanyWebsiteText
KEY CONTACTS
NAME:
░░░░░░░░░░░░░░
POSITION:
░░░░░░░░░░░░░░
PHONE:
party1Contact1PhoneText
EMAIL:
░░░░░░░░░░░░░░░░░░░░░░░░░░░
LINK:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
NAME:
party1Contact2NameText
POSITION:
party1Contact2PositionText
PHONE:
party1Contact2PhoneText
EMAIL:
party1Contact2EmailText
LINK:
party1Contact2LinkText
COMPANY 2 INFO
COMPANY:
░░░░░░░░░░░
ROLE:
░░░░░░░░░░░░░░░░░░░░░░░
ADDRESS:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
PHONE:
░░░░░░░░░░░░░░░░░░░░░░░
EMAIL:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
WEBSITE:
░░░░░░░░░░░░░░░░░░░░░░░░
OTHER LINKS:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
KEY CONTACTS
NAME:
░░░░░░░░░░░░░
POSITION:
░░░░░░░░░░░░░░
PHONE:
party1Contact1PhoneText
EMAIL:
party1Contact1EmailText
LINK:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
NAME:
░░░░░░░░░░░░░░
POSITION:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
PHONE:
party1Contact2PhoneText
EMAIL:
░░░░░░░░░░░░░░░░░░░░░░░░░░
LINK:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Location
Locations shown on the map are for indicative purposes and may vary from actual locations.
Other important details
Khan-Tengri Biopharma was incorporated on March 6, 2025, just a few months before it appeared on the agenda of the Investment Headquarters. Officially, the company is building a full-cycle biopharmaceutical complex in the Alatau free Economic Zone, but there is no information about its production facilities and completed projects. The State Revenue Committee evaluates the tax risk as average. The company is headed by Askar Karimullin, who previously held senior positions at the Samruk-Kazyna Fund and BTA Bank. Until April 21, 2025, Karimullin was the sole founder, after which TengriX Ltd., which he also headed, joined the company as a co-founder. Co-owners of TengriX Ltd. These are Khan Tengri Capital, R-Pharm JSC and Sima Ltd.
The project involves the conclusion of an investment agreement with the Government of Kazakhstan and its implementation within three years. The products will be supplied not only to the domestic market of Kazakhstan, but also for export.
The company has committed to reducing the cost of medicines for consumers by about 20% every three years, offsetting this through exports.
The project is planned to be implemented in the new city of Alatau, the site for which has already been allocated. This was announced by Nikolay Zemskov, director of R-Pharma, on the sidelines of KGIR-2025, the government's press service reports.
"We have created a joint venture that is awaiting the conclusion of an investment agreement with the Government of the Republic of Kazakhstan. The project was approved by the investment headquarters. We were given a plot of land in the most promising city of the future, Alatau," Nikolai Zemskov said.
Sources
░░░░░░░░░░░░░░
░░░░░░░░░░░░░░
░░░░░░░░░░░░░░
░░░░░░░░░░░░░░
